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Abstract: Aims
Remodelling of the cardiovascular system (including heart and vasculature) is a
dynamic process influenced by multiple physiological and pathological factors. We
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sought to understand whether remodelling in response to a stimulus, exercise training,
altered with healthy ageing.
Methods
237 untrained healthy male and female subjects volunteering for their first-time
marathon were recruited. At baseline and after 6 months of unsupervised training, race
completers underwent tests including 1.5T cardiac magnetic resonance, brachial and
non-invasive central blood pressure (BP) assessment. For analysis, runners were
divided by age into under or over 35 years (U35, O35).
Results
Injury and completion rates were similar among groups. 138 runners (U35: n=71,
females=49%; O35: n=67, females=51%) completed the race. On average, U35 were
faster by 37 minutes (12%). Training induced a small left ventricle (LV) mass increase
in both groups (3g/m  2  , p<0.001), but U35 also increased ventricular cavity sizes (LV
end-diastolic volume [EDV]i +3%; LV end-systolic volume [ESV]i +8%; right ventricle
[RV] EDVi +4%, RVESVi +5%; p<0.01 for all). Systemic aortic compliance fell in the
whole sample by 7% (p=0.020) and, especially in O35, also systemic vascular
resistance (-4% in the whole sample, p=0.04) and blood pressure (systolic/diastolic,
whole sample: brachial -4/-3 mmHg, central -4/-2 mmHg, all p <0.001; O35: brachial -
6/-3 mmHg, central -6/-4 mmHg, all p<0.001).
Conclusion
Medium-term, unsupervised, moderate intensity physical training in healthy sedentary
individuals induces measurable remodelling of both heart and vasculature. This
amount is age dependent, with predominant cardiac remodelling when younger and
predominant vascular when older.
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Abstract  
Aims: Remodeling of the cardiovascular system (including heart and vasculature) is a dynamic 
process influenced by multiple physiological and pathological factors. We sought to understand 
whether remodeling in response to a stimulus, exercise training, altered with healthy ageing. 
Methods: 237 untrained healthy male and female subjects volunteering for their first-time marathon 
were recruited. At baseline and after 6 months of unsupervised training, race completers underwent 
tests including 1.5T cardiac magnetic resonance, brachial and non-invasive central blood pressure 
(BP) assessment. For analysis, runners were divided by age into under or over 35 years (U35, O35). 
Results: Injury and completion rates were similar among groups. 138 runners (U35: n=71, 
females=49%; O35: n=67, females=51%) completed the race. On average, U35 were faster by 37 
minutes (12%). Training induced a small increase in left ventricle (LV) mass in both groups (3g/m2, 
p<0.001), but U35 also increased ventricular cavity sizes (LV end-diastolic volume [EDV]i +3%; LV 
end-systolic volume [ESV]i +8%; right ventricle [RV] EDVi +4%, RVESVi +5%; p<0.01 for all). 
Systemic aortic compliance fell in the whole sample by 7% (p=0.020) and, especially in O35, also 
systemic vascular resistance (-4% in the whole sample, p=0.04) and blood pressure (systolic/diastolic, 
whole sample: brachial -4/-3 mmHg, central -4/-2 mmHg, all p <0.001; O35: brachial -6/-3 mmHg, 
central -6/-4 mmHg, all p<0.001). 
Conclusion: Medium-term, unsupervised physical training in healthy sedentary individuals induces 
measurable remodeling of both heart and vasculature. This amount is age dependent, with 
predominant cardiac remodeling when younger and predominant vascular when older.  
 
Keywords: 
1) Physical training; 2) Cardiac remodeling; 3) Vascular remodeling; 4) Healthy ageing;  
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Introduction  
“Cardiac plasticity” is the ability of the myocardium to undergo reversible structural and functional 
changes via “remodeling”, a process that appears evolved to optimize performance.[1] It starts at the 
molecular level and leads to changes in myocytes, but also affects the extracellular compartments,[2]–
[6] translating into changes in wall thickness, chambers volumes and ventricular function which can, 
in some cases, double the size of the heart.[1] Similar plasticity is found in the vascular tree where 
macroscopically measurable changes in large vessels occur, including intima-media thickness, 
media-to-lumen ratio and elastic properties.[7]  
The overall cardiovascular phenotype at any given time is determined by age, sex, [8] environmental 
factors (for example sedentary vs athletic), disease and genetics.[9][10], [11] Our knowledge of their 
relative contributions is incomplete. Ageing-related cardiac changes include a reduction in myocyte 
numbers (30% fall from second to seventh decade)[3],[2] with hypertrophy of remaining cells in 
addition to alterations in contractile proteins and collagen, leading to a stiffer heart.[6], [12] Vascular 
changes include reduced capillary density, altered collagen and elastin, and an increase in vascular 
stiffness, with increased peripheral resistance.[7] The two compartments interact directly via vascular 
coupling (volume and pressure loading) and through paracrine and neurohumoral control.[13], [14]  
These changes may be reversible and plastic, but current knowledge is incomplete.  Physiological 
exercise can explore the system: intense physical exercise leads to the “athlete’s heart”, while 
moderate training has been associated with increased capillarity, enlargement of conduit vessels [15] 
and delayed age-related increase in cardiac stiffening.[16]  
Society is currently changing with 1) demographic ageing, with 22% of people expected to be over 
65 by 2040;[17] 2) activity changes, i.e. increasingly sedentary lifestyles for some and increasing 
recreational running in others;[18] 3) altering emergent disease profiles, e.g. heart failure with 
preserved ejection fraction (HFpEF).[19] Accordingly, we wished to explore the relationship between 
healthy ageing and differences in cardiovascular adaptation in response to a stimulus, here moderate, 
unsupervised, medium-term aerobic exercise. 
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Methods 
This was a prospective observational study, evaluating first-time marathon runners of both sexes, 
unaware of pre-existing cardiovascular conditions and not on medications, sedentary. Exclusion 
criteria included cardiovascular disease uncovered during preliminary investigations and 
contraindication to cardiac magnetic resonance (CMR).  The study was advertised by email over 2 
consecutive years to novice marathon runners, identified through the database records of the Virgin 
Money London Marathon, and on social media. Interested runners contacted a dedicated call center 
and were given an appointment for eligibility assessment and recruitment. 
The study protocol has already been described [20]–[23]. Briefly, it included: 
1) cardiopulmonary exercise test (CPET) using a semi-recumbent tilting cycle ergometer (Schiller 
ERG 911 BP/LS, Schiller, Switzerland) and a dedicated metabolic cart (Quark CPET, COSMED, 
Rome, Italy).[24] 
2) Allometry and bioimpedance (BC-418, Tanita, USA),  
3) Cardiac magnetic resonance (CMR) (1.5T Aera, Siemens Medical Solution, Erlangen, Germany), 
performed accordingly to international guidelines,[25] including parametric T1 mapping and 
extracellular volume (ECV), pulse wave velocity (PWV) measured with phase-contrast MR imaging 
and late gadolinium enhancement (LGE) images.[26] Image analysis was performed by 3experienced 
operators. See Table S2 for intra- and inter- operator reproducibility data. 
4) Brachial and non-invasive central- blood pressure (BP) assessment and wave analysis using a 
Cardioscope II BP+ device (USCOM, Sydney, NSW, Australia).[27] 
5) Hematocrit and serum creatinine.  
 
Systemic vascular resistance (SVR) and systemic aortic compliance (SAC) were also calculated as 
follows:  
𝑆𝑉𝑅 =
𝑀𝐴𝑃
𝐶𝑂
∗ 80 
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𝑆𝐴𝐶 =
𝑆𝑉
𝑆𝐵𝑃 − 𝐷𝐵𝑃
 
 
Where SVR: systemic vascular resistance; MAP: mean arterial pressure; CO: cardiac output; SAC: 
systemic arterial compliance, SBP: systolic BP; DBP: diastolic BP. 
All measurements were carried out before training started, 6months before the marathon, and repeated 
between 1 and 3weeks after the race, to avoid the acute effects of the race.  It was recommended that 
participants followed the race organisers’ “Beginner’s Training Plan” (see Appendix 1), but 
alternative training plans were allowed. The calculation of synthetic ECV [28] was preferred because 
haematocrit, needed in order to calculate normal ECV, was unavailable at follow-up in 35 subjects 
due to the cyberattack that affected NHS and the hospital laboratory immediately before the study 
dates.  
All procedures were in accordance with the principles of the Helsinki declaration, all participants 
gave written informed consent, and the study was approved by the London-Queen Square National 
Research Ethics Service Committee(15/LO/0086). 
 
Statistical analysis 
Quantitative variables are expressed as mean±standard deviation (SD) or (range) and categorical 
variables as an absolute number with percentage in parentheses. Only the subjects who completed the 
study were included in the analysis. To assess the cardiovascular effects of aerobic exercises in 
different age group, we used linear mixed-effects models accounting for repeated measurements with 
an unstructured covariance matrix, fitting the models by maximizing the restricted log-likelihood 
followed by a posteriori contrasts when applicable. False Discovery Rate algorithm was used for 
multiple post-hoc comparisons. The variables were transformed to handle possible violations of the 
hypothesis of normality of the residuals. For analysis of the age effect, we split recruited runners into 
two groups, “under 35” (U35) and “over 35” (O35), when a runner is <35 or ≥35 years respectively, 
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 6 
accordingly to the classification of “young” versus “master” athlete. Linear regression analysis was 
also performed (results in Appendix 2). An α level of 0.05 was used for all hypothesis tests; analyses 
were performed using R Core Team software (2018), Vienna, Austria. 
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Results 
Study population 
Two hundred and thirty-seven runners were recruited. Among them 166 (70%) completed the race, 
52 (22%) interrupted their training following musculoskeletal injury, 19 (8%) did not compete for 
other reasons. Among the race completers, 27did not attend for follow-up, 1 was excluded after being 
diagnosed with hypertension. The final cohort consisted of 138 subjects who underwent evaluations 
at 180±10 days before the London Marathon and 16±8 days after (Figure 1). Baseline mean age was 
37±10years (range 21-69y.o.), 51% were females (mean age 37±10years, 47% <35years), 49% were 
males (mean age 37±11years, 54% <35years). Reported median hours of training per week were 1.9.  
See Table 1 for full details. 
 
Baseline characteristics 
We did not find any significant difference in the baseline characteristics between the subjects who 
completed the study or dropped out. Race finishers were similar in age and gender (U35: n=71, mean 
age 29±4y, females=49%; O35: n=67, mean age 46±7y, females=51%). The prevalence of former 
smokers was lower in U35 than in O35 (10% vs 32% respectively, p =0.002). No differences were 
observed for ethnicity and blood tests results. See Table 1 and 2.  
Marathon completion rate and injury rate during training did not differ between age groups (Figure 
1).  Mean race time (HH:MM) was 4:44 (range: 2:57-7:57) in the whole cohort. U35 were faster 
(mean race time in U35: 4:38 [range 2:56–6:51] against 5:15 [range 3:27–7:57] in O35).  
All participants achieved an RER of 1.1 or greater at the baseline CPET. Age predicted peak oxygen 
uptake was 109±17%, without significant differences between groups, although absolute physical 
performance was superior in U35 than in O35 for peak oxygen uptake (+5.6 ml/kg/min, p<0.001), 
maximal reached power (+13W, p=0.012) and exercise time (+166 seconds, p<0.001).   
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 Mean height, weight, body surface area (BSA) did not differ between groups. On average, body mass 
index (BMI) was high-normal (24.4, range 16.7-35.2), and lower in U35 than O35 (U35: 23.6±0.3; 
O35: 25.1±0.4, p=0.009).  
Average biventricular chambers size and LV mass indexed for BSA were normal in the whole 
sample.[29] All volumes and mass were higher in U35 than in O35 (LV EDVi: +8ml/m2; LV ESVi: 
+5ml/m2, RV EDVi and ESVi: +10ml/m2; LV mass +6gr/m2; p<0.001 for all). Native T1 values and 
synthetic ECV were within the normal range and not different between groups.[26] There was basal 
infero-lateral mid-myocardial non-ischemic LGE in one male subject in the O35, both before and 
after training (unchanged).  
Average BP was normal in the whole sample, but lower in U35 than in O35 by 5/3mmHg for brachial 
SBP/DBP (p=0.02/0.03 respectively) and by 6/3mmHg for central SBP/DBP (p=0.004 for cSBP and 
p=0.03 for cDBP). Arterial PWV in the whole aorta was 6±15m/s, lower in U35 than O35 by 1.4m/sec 
(p <0.001).[20] Similarly, SVR were on average 1135dyn·s/cm5, significantly lower in U35 than in 
O35 by 173dyn·s/cm5 (p <0.001). Finally, SAC of the whole sample was 3.0 ±8 ml/m2, higher in U35 
than in O35 (+0.3 ml/m2, p=0.001). 
See Table 2 and Table S1.  
 
Follow up 
Cardiopulmonary exercise testing 
After training, there were small increases in overall fitness. Mild improvement was observed in peak 
oxygen uptake (+1ml/kg/min, p=0.035). Exercise time increased on average by 21seconds (p=0.010) 
and peak power by 4W (p=0.002). Subgroup analysis showed these changes in the U35 only (exercise 
time: +6%, peak power: +5%, peak VO2 +3%; p<0.01, p<0.01 and p<0.05 respectively). Resting 
heart rate was unchanged at follow-up. 
 
Allometry 
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After training, weight fell by 900g (p=0.001) and body fat by 1% (p=0.006) driven by O35 (on 
average -2%, p<0.001). Height decreased by 6mm in both groups. See Table2. 
 
Cardiac remodeling 
After training, biventricular volumes increased by an average of 2ml/m2 (EDVi) and 1ml/m2 (ESVi) 
(p<0.05 for both). At post hoc analysis, the chambers size increase was observed only in the U35 
(LVEDVi: +3%, LVESVi: +8%, RVEDVi: +4%, RVESVi: +5%, p<0.001 for all), while no change 
was observed in O35. A similar 4% (~3g/m2) increase in LV mass was observed in both groups 
(p<0.001) representing mild concentric remodeling (LV mass/volume ratio increase of 0.2), driven 
by O35, in whom LV mass/volume ratio went from 0.73±0.1 to 0.76±0.1 (p=0.001).  
Synthetic ECV and native myocardial T1 mapping were unchanged after training.  No changes were 
observed in the myocardial partition coefficient, post-contrast T1 myocardial, full blood count or 
kidney function in either group. 
See Table 2 and Table 1S.  
 
Systemic hemodynamics and vascular remodeling.  
There was a mean 4% decrease in SVR after training (p=0.04), driven by O35 (baseline vs follow-up 
in U35: p=0.31; O35: p=0.060;), associated with a 7% reduction in SAC (p=0.020), similar in U35 
and O35 (baseline vs follow-up p=0.002 for both), and a mild reduction in the PWV of the whole 
aorta (p=0.040), without differences between age groups. Training reduced BP, with the largest falls 
observed in O35. Brachial SBP/DBP dropped by 3/1mmHg in U35 (p=0.030 for SBP, p=0.08 for 
DBP) and by 6/3mmHg in O35 (p<0.001 for both SBP and DBP); central SBP/DBP dropped by 
3/2mmHg in U35 (p=0.05 for SBP, p=0.004 for DBP) and dropped by 6/4mmHg in O35 (p<0.001 
for both SBP and DBP). 
See Table 2 and Table S1.  
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Discussion 
 
This study explored the cardiac and vascular remodeling occurring in healthy sedentary adults of 
different age groups undergoing medium-term, unsupervised physical training of mild intensity. Our 
main findings were a more pronounced cardiac remodeling observed in younger subjects and more 
vascular changes, associated with early cardiac remodeling features, in older subjects (Figure 2). 
Specifically, the U35 showed an increase in ventricular LV size consistent with 6-months of 
endurance training in a similar age-group,[30] associated with an increase in LV mass consistent with 
a light training schedule and a very mild reduction in BP. On the other hand, in the O35s only early 
cardiac remodeling was noted (i.e. a  LV mass increase similar to O35 but no measurable cavity 
dilatation), associated with a more marked reduction in BP and SVR, corresponding to the effect of 
a low-dose BP lowering drug on BP and to an overall reduction in vascular age of approximately four 
years. [20],[21], [31] 
Ageing is associated with impaired cardiovascular elasticity [32],[7] and reduced cardiac responsivity 
to sympathetic stimulation.[33] Histologically, these features correspond to 1) quantitative and 
qualitative changes in collagen, 2) a reduction in cardiomyocyte number with compensatory 
hypertrophy of the remaining cells [1] and 3) changes in cardiac innervation.[6], [12] Functionally, 
this translates into cardiac diastolic dysfunction and dromotropic/inotropic impairment, associated 
with increased afterload and leading to increased ventricular filling pressure and impaired exercise 
tolerance. Combined, cardiac and vascular ageing is critical in determining exercise tolerance: in fact, 
the impairment in cardiac response during strenuous exercise observed in aged people [34] is entirely 
reversible by reducing the loading conditions. [35]  
On the other hand, endurance training is known to increase stroke volume, improve endothelial 
function and coronary perfusion, decrease peripheral resistance, lower blood pressure and induce 
cardiac and skeletal muscle cell remodeling. [15], [32], [36] 
Here, in the O35 group, we observed an improvement in vascular function, and peripheral resistance, 
consistent with previous observations. [37] We hypothesize that mild-intensity training may unload 
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the myocardium and improve ventriculo-arterial coupling, thereby increasing cardiovascular 
efficiency meaning that stimulated cardiac growth was counteracted – an overall beneficial set of 
linked changes.[38]  
For the U35s, possessing a greater number of smaller myocytes, an effective response to sympathetic 
stimulation and loading conditions already well coupled to vascular function, a mild increase in LV 
volumes along the lines expected for “athlete’s heart” was seen.[39], [40] 
Finally, no changes in ECV were observed in different study conditions, arguably because any 
changes were proportionate with equal changes in intracellular and extracellular compartments or 
because the amount of exercise undertaken was insufficient to induce a measurable change in the 
cellular/extracellular tissue component ratio.[41]  
We acknowledge a number of limitations, including the lack of a non-running control group, a 
potential selection bias related to the availability to take part in a research study and the lack of ethnic 
diversity. Here, the U35s and O35s were all first-time marathon runners, but they differ by more than 
just age. Although it is not possible to fully unravel the contribution of differences (birth cohort bias 
with different nutrition, gestational conditions and lifestyle, as suggested by ex-smoker rates different 
between cohorts; baseline fitness; training schedule; commitment; age-related whole-organism 
responsivity to training) and the net amount of physical exercise against age in determining 
cardiovascular remodeling, baseline age adjusted peak oxygen consumption and marathon 
completion and injury rates were not age dependent, suggesting that baseline fitness, training 
schedules and commitment were not the primary cause of the remodeling differences. Actual physical 
activity during the training period is unknown due to excessive number of missing data, but average 
completion times exceed those reported in age-matched wide cohorts (including professionals 
athletes) by ~40 minutes in U35 and by ~70 minutes in O35,[18] suggesting that training intensity 
was mild. Exercise-induced cardiovascular remodeling is dose-dependent, with mass increase 
observed earlier than volume increase. [30] The mild amount of cardiovascular remodeling observed 
is proportional to the entity of training undertaken, and more marked changes would have been 
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unexpected. We believe that the potential significance of our results is also related to their 
epidemiological impact: this kind and entity of exercise is generalizable to the real-world population 
and is feasible outside a structured training program.  
Finally, the study had a high drop-out rate (42%), mostly due to musculoskeletal injury (71% of total 
drop-out). We did not find any differences between study completers and non-completers at baseline 
examination (Table 3S), thus excluding a selection bias were study completers could be a selection 
of the cohort with better cardiovascular adaptation to exercise. 
With the aforementioned limitations, this study may contribute to cardiac rehabilitation research, 
where vascular function and peripheral resistance changes could be tested as an efficacy endpoint. 
There may also be relevance to HFpEF, where a component of reversible vascular dysfunction may 
explain the benefits observed after physical training despite unchanged cardiac function – the idea 
that at least some HFpEF has a significant and reversible vascular dysfunction component is not 
widely considered.[42], [43] Additional points that need clarification are the mechanisms underlying 
these observations and the impact of sex on cardiovascular ageing and its interaction with physical 
exercise. [37], [44] 
In conclusion, these data show how different age groups shift on the training-induced cardiovascular 
remodeling spectrum, with more relevant cardiac changes observed in the youth, resembling an early 
athlete’s heart phenotype, and more vascular changes, tending to improved efficiency through 
optimization of cardiac load and corresponding to a decrease in vascular age, in the elderly.    
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Figure Legends: 
 
Figure 1: Consort flow diagram illustrating subject recruitment and follow up. LQTS, long QT 
syndrome. U35: Under 35, <35 years old. O35: Over 35, ≥ 35 years old. 
 
Figure 2: Effects of ageing and physical training on the continuum of cardiovascular system 
remodeling. Panel 1: cardiac and vascular assessment by cardiac magnetic resonance (A: extracellular 
volume. B: function and mass; C, D, E: vascular function acquisitions to derive pulse wave velocity 
and arterial compliance by obtaining distance and high temporal resolution [G] flow and using least 
squares estimate of systolic upslopes [F]. Graphical schematics of systemic vascular resistance [H]). 
Panel 2: healthy ageing is characterized by a reduction in myocytes number, compensatory 
hypertrophy, and collagen alterations with vascular changes of arterial stiffening, increased pulse 
wave velocity, reduced arterial compliance and increased systemic vascular resistance. Physical 
training here induced cardiac plasticity (increase in left ventricular mass and chambers volume) in 
individuals <35years (U35), with minimal blood pressure changes (panel 1 to 3). In individuals aged 
≥35 years (O35), more vascular plasticity (systemic vascular resistance drop, systemic blood pressure 
drops) along with mild left ventricular mass increase (panel 2 to 4) are observed. 
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Abstract (249 words, max 250) 
Aims: RemodellingRemodeling of the cardiovascular system (including heart and vasculature) is a 
dynamic process influenced by multiple physiological and pathological factors. We sought to 
understand whether remodellingremodeling in response to a stimulus, exercise training, altered with 
healthy ageing. 
Methods: 237 untrained healthy male and female subjects volunteering for their first-time marathon 
were recruited. At baseline and after 6 months of unsupervised training, race completers underwent 
tests including 1.5T cardiac magnetic resonance, brachial and non-invasive central blood pressure 
(BP) assessment. For analysis, runners were divided by age into under or over 35 years (U35, O35). 
Results: Injury and completion rates were similar among groups. 138 runners (U35: n=71, 
females=49%; O35: n=67, females=51%) completed the race. On average, U35 were faster by 37 
minutes (12%). Training induced a small increase in left ventricle (LV) mass in both groups (3g/m2, 
p<0.001), but U35 also increased ventricular cavity sizes (LV end-diastolic volume [EDV]i +3%; LV 
end-systolic volume [ESV]i +8%; right ventricle [RV] EDVi +4%, RVESVi +5%; p<0.01 for all). 
Systemic aortic compliance fell in the whole sample by 7% (p=0.020) and, especially in O35, also 
systemic vascular resistance (-4% in the whole sample, p=0.04) and blood pressure (systolic/diastolic, 
whole sample: brachial -4/-3 mmHg, central -4/-2 mmHg, all p <0.001; O35: brachial -6/-3 mmHg, 
central -6/-4 mmHg, all p<0.001). 
Conclusion: Medium-term, unsupervised physical training in healthy sedentary individuals induces 
measurable remodellingremodeling of both heart and vasculature. This amount is age dependent, with 
predominant cardiac remodellingremodeling when younger and predominant vascular when older.  
 
Keywords: 
1) Physical training; 2) Cardiac remodellingremodeling; 3) Vascular remodellingremodeling; 4) 
Healthy ageing;  
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Introduction  
“Cardiac plasticity” is the ability of the myocardium to undergo reversible structural and functional 
changes via “remodellingremodeling”, a process that appears evolved to optimize performance.[1] It 
starts at the molecular level and leads to changes in myocytes, but also affects the extracellular 
compartments,[2]–[6] translating into changes in wall thickness, chambers volumes and ventricular 
function which can, in some cases, double the size of the heart.[1] Similar plasticity is found in the 
vascular tree where macroscopically measurable changes in large vessels occur, including intima-
media thickness, media-to-lumen ratio and elastic properties.[7]  
The overall cardiovascular phenotype at any given time is determined by age, sex, [8] environmental 
factors (for example sedentary vs athletic), disease and genetics.[9][10], [11] Our knowledge of their 
relative contributions is incomplete. Ageing-related cardiac changes include a reduction in myocyte 
numbers (30% fall from second to seventh decade)[3],[2] with hypertrophy of remaining cells in 
addition to alterations in contractile proteins and collagen, leading to a stiffer heart.[6], [12] Vascular 
changes include reduced capillary density, altered collagen and elastin, and an increase in vascular 
stiffness, with increased peripheral resistance.[7] The two compartments interact directly via vascular 
coupling (volume and pressure loading) and through paracrine and neurohumoral control.[13], [14]  
These changes may be reversible and plastic, but current knowledge is incomplete.  Physiological 
exercise can explore the system: intense physical exercise leads to the “athlete’s heart”, while 
moderate training has been associated with increased capillarity, enlargement of conduit vessels [15] 
and delayed age-related increase in cardiac stiffening.[16]  
Society is currently changing with 1) demographic ageing, with 22% of people expected to be over 
65 by 2040;[17] 2) activity changes, i.e. increasingly sedentary lifestyles for some and increasing 
recreational running in others;[18] 3) altering emergent disease profiles, e.g. heart failure with 
preserved ejection fraction (HFpEF).[19] Accordingly, we wished to explore the relationship between 
healthy ageing and modalities and differences in cardiovascular adaptation in response to a stimulus, 
here moderate, unsupervised, medium-term aerobic exercise. 
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Methods 
This was a prospective observational study, evaluating first-time marathon runners of both sexes, 
unaware of pre-existing cardiovascular conditions and not on medications, sedentary. Exclusion 
criteria included cardiovascular disease uncovered during preliminary investigations and 
contraindication to cardiac magnetic resonance (CMR).  The study was advertised by email over 2 
consecutive years to novice marathon runners, identified through the database records of the Virgin 
Money London Marathon, and on social media. Interested runners contacted a dedicated call center 
and were given an appointment for eligibility assessment and recruitment. 
The study protocol has already been described [20]–[23][20]–[22]. Briefly, it included: 
1) cardiopulmonary exercise test (CPET) using a semi-recumbent tilting cycle ergometer (Schiller 
ERG 911 BP/LS, Schiller, Switzerland) and a dedicated metabolic cart (Quark CPET, COSMED, 
Rome, Italy).[24][23] 
2) Allometry and bioimpedance (BC-418, Tanita, USA),  
3) Cardiac magnetic resonance (CMR) (1.5T Aera, Siemens Medical Solution, Erlangen, Germany), 
performed accordingly to international guidelines,[25][24] including parametric T1 mapping and 
extracellular volume (ECV), pulse wave velocity (PWV) measured with phase-contrast MR imaging 
and late gadolinium enhancement (LGE) images.[26][25] Image analysis was performed by 
3experienced operators. See Table S2 for intra- and inter- operator reproducibility data. 
4) Brachial and non-invasive central- blood pressure (BP) assessment and wave analysis using a 
Cardioscope II BP+ device (USCOM, Sydney, NSW, Australia).[27][26] 
5) Hematocrit and serum creatinine.  
 
Systemic vascular resistance (SVR) and systemic aortic compliance (SAC) were also calculated as 
follows:  
𝑆𝑉𝑅 =
𝑀𝐴𝑃
𝐶𝑂
∗ 80 
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 5 
𝑆𝐴𝐶 =
𝑆𝑉
𝑆𝐵𝑃 − 𝐷𝐵𝑃
 
 
Where SVR: systemic vascular resistance; MAP: mean arterial pressure; CO: cardiac output; SAC: 
systemic arterial compliance, SBP: systolic BP; DBP: diastolic BP. 
All measurements were carried out before training started, 6months before the marathon, and repeated 
between 1 and 3weeks after the race, to avoid the acute effects of the race.  It was recommended that 
participants followed the race organisers’ “Beginner’s Training Plan” (see Appendix 1), but 
alternative training plans were allowed. The calculation of synthetic ECV [28][27] was preferred 
because haematocrit, needed in order to calculate normal ECV, was unavailable at follow-up in 35 
subjects due to the cyberattack that affected NHS and the hospital laboratory immediately before the 
study dates.  
All procedures were in accordance with the principles of the Helsinki declaration, all participants 
gave written informed consent, and the study was approved by the London-Queen Square National 
Research Ethics Service Committee(15/LO/0086). 
 
Statistical analysis 
Quantitative variables are expressed as mean±standard deviation (SD) or (range) and categorical 
variables as an absolute number with percentage in parentheses. Only the subjects who completed the 
study were included in the analysis. To assess the cardiovascular effects of aerobic exercises in 
different age group, we used linear mixed-effects models accounting for repeated measurements with 
an unstructured covariance matrix, fitting the models by maximizing the restricted log-likelihood 
followed by a posteriori contrasts when applicable. False Discovery Rate algorithm was used for 
multiple post-hoc comparisons. The variables were transformed to handle possible violations of the 
hypothesis of normality of the residuals. For analysis of the age effect, we split recruited runners into 
two groups, “under 35” (U35) and “over 35” (O35), when a runner is <35 or ≥35 years respectively, 
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 6 
accordingly to the classification of “young” versus “master” athlete. Linear regression analysis was 
also performed (results in Appendix 2). An α level of 0.05 was used for all hypothesis tests; analyses 
were performed using R Core Team software (2018), Vienna, Austria. 
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Results 
Study population 
Two hundred and thirty-seven runners were recruited. Among them 166 (70%) completed the race, 
52 (22%) interrupted their training following musculoskeletal injury, 19 (8%) did not compete for 
other reasons. Among the race completers, 27did not attend for follow-up, 1 was excluded after being 
diagnosed with hypertension. The final cohort consisted of 138 subjects who underwent evaluations 
at 180±10 days before the London Marathon and 16±8 days after (Figure 1). Baseline mean age was 
37±10years (range 21-69y.o.), 51% were females (mean age 37±10years, 47% <35years), 49% were 
males (mean age 37±11years, 54% <35years). Reported median hours of training per week were 1.9.  
See Table 1 for full details. 
 
Baseline characteristics 
We did not find any significant difference in the baseline characteristics between the subjects who 
completed the study or dropped out. Race finishers were similar in age and gender (U35: n=71, mean 
age 29±4y, females=49%; O35: n=67, mean age 46±7y, females=51%). The prevalence of former 
smokers was lower in U35 than in O35 (10% vs 32% respectively, p =0.002). No differences were 
observed for ethnicity and blood tests results. See Table 1 and 2.  
Marathon completion rate and injury rate during training did not differ between age groups (Figure 
1).  Mean race time (HH:MM) was 4:44 (range: 2:57-7:57) in the whole cohort. U35 were faster 
(mean race time in U35: 4:38 [range 2:56–6:51] against 5:15 [range 3:27–7:57] in O35).  
All participants achieved an RER of 1.1 or greater at the baseline CPET. Age predicted peak oxygen 
uptake was 109±17%, without significant differences between groups, although absolute physical 
performance was superior in U35 than in O35 for peak oxygen uptake (+5.6 ml/kg/min, p<0.001), 
maximal reached power (+13W, p=0.012) and exercise time (+166 seconds, p<0.001).   
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 Mean height, weight, body surface area (BSA) did not differ between groups. On average, body mass 
index (BMI) was high-normal (24.4, range 16.7-35.2), and lower in U35 than O35 (U35: 23.6±0.3; 
O35: 25.1±0.4, p=0.009).  
Average biventricular chambers size and LV mass indexed for BSA were normal in the whole 
sample.[29][28] All volumes and mass were higher in U35 than in O35 (LV EDVi: +8ml/m2; LV 
ESVi: +5ml/m2, RV EDVi and ESVi: +10ml/m2; LV mass +6gr/m2; p<0.001 for all). Native T1 
values and synthetic ECV were within the normal range and not different between groups.[26][25] 
There was basal infero-lateral mid-myocardial non-ischemic LGE in one male subject in the O35, 
both before and after training (unchanged).  
Average BP was normal in the whole sample, but lower in U35 than in O35 by 5/3mmHg for brachial 
SBP/DBP (p=0.02/0.03 respectively) and by 6/3mmHg for central SBP/DBP (p=0.004 for cSBP and 
p=0.03 for cDBP). Arterial PWV in the whole aorta was 6±15m/s, lower in U35 than O35 by 1.4m/sec 
(p <0.001).[20] Similarly, SVR were on average 1135dyn·s/cm5, significantly lower in U35 than in 
O35 by 173dyn·s/cm5 (p <0.001). Finally, SAC of the whole sample was 3.0 ±8 ml/m2, higher in U35 
than in O35 (+0.3 ml/m2, p=0.001). 
See Table 2 and Table S1.  
 
Follow up 
Cardiopulmonary exercise testing 
After training, there were small increases in overall fitness. Mild improvement was observed in peak 
oxygen uptake (+1ml/kg/min, p=0.035). Exercise time increased on average by 21seconds (p=0.010) 
and peak power by 4W (p=0.002). Subgroup analysis showed these changes in the U35 only (exercise 
time: +6%, peak power: +5%, peak VO2 +3%; p<0.01, p<0.01 and p<0.05 respectively). Resting 
heart rate was unchanged at follow-up. 
 
Allometry 
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After training, weight fell by 900g (p=0.001) and body fat by 1% (p=0.006) driven by O35 (on 
average -2%, p<0.001). Height decreased by 6mm in both groups. See Table2. 
 
Cardiac remodellingremodeling 
After training, biventricular volumes increased by an average of 2ml/m2 (EDVi) and 1ml/m2 (ESVi) 
(p<0.05 for both). At post hoc analysis, the chambers size increase was observed only in the U35 
(LVEDVi: +3%, LVESVi: +8%, RVEDVi: +4%, RVESVi: +5%, p<0.001 for all), while no change 
was observed in O35. A similar 4% (~3g/m2) increase in LV mass was observed in both groups 
(p<0.001) representing mild concentric remodellingremodeling (LV mass/volume ratio increase of 
0.2), driven by O35, in whom LV mass/volume ratio went from 0.73±0.1 to 0.76±0.1 (p=0.001).  
Synthetic ECV and native myocardial T1 mapping were unchanged after training.  No changes were 
observed in the myocardial partition coefficient, post-contrast T1 myocardial, full blood count or 
kidney function in either group. 
See Table 2 and Table 1S.  
 
Systemic hemodynamics and vascular remodellingremodeling.  
There was a mean 4% decrease in SVR after training (p=0.04), driven by O35 (baseline vs follow-up 
in U35: p=0.31; O35: p=0.060;), associated with a 7% reduction in SAC (p=0.020), similar in U35 
and O35 (baseline vs follow-up p=0.002 for both), and a mild reduction in the PWV of the whole 
aorta (p=0.040), without differences between age groups. Training reduced BP, with the largest falls 
observed in O35. Brachial SBP/DBP dropped by 3/1mmHg in U35 (p=0.030 for SBP, p=0.08 for 
DBP) and by 6/3mmHg in O35 (p<0.001 for both SBP and DBP); central SBP/DBP dropped by 
3/2mmHg in U35 (p=0.05 for SBP, p=0.004 for DBP) and dropped by 6/4mmHg in O35 (p<0.001 
for both SBP and DBP). 
See Table 2 and Table S1.  
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Discussion 
 
This study explored the cardiac and vascular remodellingremodeling occurring in healthy sedentary 
adults of different age groups undergoing medium-term, unsupervised physical training of mild 
intensity. Our main findings were a more pronounced cardiac remodellingremodeling observed in 
younger subjects and more vascular changes, associated with early cardiac remodellingremodeling 
features, in older subjects (Figure 2). Specifically, the U35 showed an increase in ventricular LV size 
consistent with 6-months of endurance training in a similar age-group,[30][29] associated with an 
increase in LV mass consistent with a light training schedule and a very mild reduction in BP. On the 
other hand, in the O35s only early cardiac remodellingremodeling was noted (i.e. a  LV mass increase 
similar to O35 but no measurable cavity dilatation), associated with a more marked reduction in BP 
and SVR, corresponding to the effect of a low-dose BP lowering drug on BP and to an overall 
reduction in vascular age of approximately four years. [20],[21], [31][21], [30] 
Ageing is associated with impaired cardiovascular elasticity [32][31],[7] and reduced cardiac 
responsivity to sympathetic stimulation.[33][32] Histologically, these features correspond to 1) 
quantitative and qualitative changes in collagen, 2) a reduction in cardiomyocyte number with 
compensatory hypertrophy of the remaining cells [1] and 3) changes in cardiac innervation.[6], [12] 
Functionally, this translates into cardiac diastolic dysfunction and dromotropic/inotropic impairment, 
associated with increased afterload and leading to increased ventricular filling pressure and impaired 
exercise tolerance. Combined, cardiac and vascular ageing is critical in determining exercise 
tolerance: in fact, the impairment in cardiac response during strenuous exercise observed in aged 
people [34][33] is entirely reversible by reducing the loading conditions. [35][34]  
On the other hand, endurance training is known to increase stroke volume, improve endothelial 
function and coronary perfusion, decrease peripheral resistance, lower blood pressure and induce 
cardiac and skeletal muscle cell remodellingremodeling. [15], [32], [36][15], [31], [35] 
Here, in the O35 group, we observed an improvement in vascular function, and peripheral resistance, 
consistent with previous observations. [37] We hypothesize that mild-intensity training may unload 
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Formatted: Highlight
Formatted: Highlight
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 11 
the myocardium and improve ventriculo-arterial coupling, thereby increasing cardiovascular 
efficiency meaning that stimulated cardiac growth was counteracted – an overall beneficial set of 
linked changes.[38][36]  
For the U35s, possessing a greater number of smaller myocytes, an effective response to sympathetic 
stimulation and loading conditions already well coupled to vascular function, a mild increase in LV 
volumes along the lines expected for “athlete’s heart” was seen.[39], [40][37] 
Finally, no changes in ECV were observed in different study conditions, arguably because any 
changes were proportionate with equal changes in intracellular and extracellular compartments or 
because the amount of exercise undertaken was insufficient to induce a measurable change in the 
cellular/extracellular tissue component ratio.[41][38]  
We acknowledge a number of limitations, including the lack of a non-running control group, a 
potential selection bias related to the availability to take part in a research study and the lack of ethnic 
diversity. Here, the U35s and O35s were all first-time marathon runners, but they differ by more than 
just age. Although it is not possible to fully unravel the contribution of differences (birth cohort bias 
with different nutrition, gestational conditions and lifestyle, as suggested by ex-smoker rates different 
between cohorts; baseline fitness; training schedule; commitment; age-related whole-organism 
responsivity to training) and the net amount of physical exercise against age in determining 
cardiovascular remodellingremodeling, baseline age adjusted peak oxygen consumption and 
marathon completion and injury rates were not age dependent, suggesting that baseline fitness, 
training schedules and commitment were not the primary cause of the remodellingremodeling 
differences. Actual physical activity during the training period is unknown due to excessive number 
of missing data, but average completion times exceed those reported in age-matched wide cohorts 
(including professionals athletes) by ~40 minutes in U35 and by ~70 minutes in O35,[18] suggesting 
that training intensity was mild. Exercise-induced cardiovascular remodellingremodeling is dose-
dependent, with mass increase observed earlier than volume increase. [30][29] The mild amount of 
cardiovascular remodellingremodeling observed is proportional to the entity of training undertaken, 
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and more marked changes would have been unexpected. We believe that the potential significance of 
our results is also related to their epidemiological impact: this kind and entity of exercise is 
generalizable to the real-world population and is feasible outside a structured training program.  
Finally, the study had a high drop-out rate (42%), mostly due to musculoskeletal injury (71% of total 
drop-out). We did not find any differences between study completers and non-completers at baseline 
examination (Table 3S), thus excluding a selection bias were study completers could be a selection 
of the cohort with better cardiovascular adaptation to exercise. 
With the aforementioned limitations, this study may contribute to cardiac rehabilitation research, 
where vascular function and peripheral resistance changes could be tested as an efficacy endpoint. 
There may also be relevance to HFpEF, where a component of reversible vascular dysfunction may 
explain the benefits observed after physical training despite unchanged cardiac function – the idea 
that at least some HFpEF has a significant and reversible vascular dysfunction component is not 
widely considered.[42], [43][39], [40] Additional points that need clarification are the mechanisms 
underlying these observations and the impact of sex on cardiovascular ageing and its interaction with 
physical exercise. [37], [44] 
In conclusion, these data show how different age groups shift on the training-induced cardiovascular 
remodellingremodeling spectrum, with more relevant cardiac changes observed in the youth, 
resembling an early athlete’s heart phenotype, and more vascular changes, tending to improved 
efficiency through optimization of cardiac load and corresponding to a decrease in vascular age, in 
the elderly.    
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Figure Legends: 
 
Figure 1: Consort flow diagram illustrating subject recruitment and follow up. LQTS, long QT 
syndrome. U35: Under 35, <35 years old. O35: Over 35, ≥ 35 years old. 
 
Figure 2: Effects of ageing and physical training on the continuum of cardiovascular system 
remodellingremodeling. Panel 1: cardiac and vascular assessment by cardiac magnetic resonance (A: 
extracellular volume. B: function and mass; C, D, E: vascular function acquisitions to derive pulse 
wave velocity and arterial compliance by obtaining distance and high temporal resolution [G] flow 
and using least squares estimate of systolic upslopes [F]. Graphical schematics of systemic vascular 
resistance [H]). Panel 2: healthy ageing is characterized by a reduction in myocytes number, 
compensatory hypertrophy, and collagen alterations with vascular changes of arterial stiffening, 
increased pulse wave velocity, reduced arterial compliance and increased systemic vascular 
resistance. Physical training here induced cardiac plasticity (increase in left ventricular mass and 
chambers volume) in individuals <35years (U35), with minimal blood pressure changes (panel 1 to 
3). In individuals aged ≥35 years (O35), more vascular plasticity (systemic vascular resistance drop, 
systemic blood pressure drops) along with mild left ventricular mass increase (panel 2 to 4) are 
observed. 
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  Whole cohort U35 (≤34 years) O35 (≥35 years) 
n  138 71 67 
Age (years)  37 (21-69) 29 ±4 46 ±7 
Female  70 (51%) 34 (49%) 36 (51%) 
Male  68 (49%) 37 (54%) 31 (46%) 
Ethnicity        
     White  125 (91%) 62 (93%) 63 (89%) 
     Asian  4 (4%) 1 (1%) 3 (4%) 
     Black  3 (2%) 2 (2%) 1 (1%) 
     Mixed  4 (3%) 0  4 (5%) 
     Other  2 (1%) 0  2 (2%) 
Smoking        
      Non-smoker  102 (74%) 60 (85%) 42 (63%) 
      Current smoker  7 (5%) 4 (5bhuva%) 3 (5%) 
      Ex-smoker  29 (21%) 7 (10%) 22 (32%) 
Exercise / week (hrs)  1.9 (0-10) 1.8 (0-4) 2 (0-10) 
Running Time (hrs:mins)  4:44 (2:57 – 7:57) 4:38 (2:56-6:51) 5:15 (3:27 – 7:57) 
        
 
Table 1: Baseline characteristics of study participants in the final cohort, stratified by age category. Data are expressed as mean (range), mean 
±SD or number (%).  
 
Table 1
  
 
Whole cohort 
(n= 138) 
 
U35 (≤34 years) 
(n= 71)  
 
O35 (≥35 years) 
(n= 67) 
 
p 
condition 
p 
age 
p 
interaction 
Allometry Timepoint               
Height (cm) Baseline 172.9 ± 9.5 174.3 ± 9.5   171.6 ± 9.4   0.001 0.09 0.8 
  Follow-up 172.4 ± 9.5 173.7 ± 9.5 * 171.0 ± 9.5 **       
Weight (kg) Baseline 73.2 ± 13 71.8 ± 12  74.5 ± 15  0.001 0.1 0.04 
 Follow-up 72.3 ± 12 71.4 ± 10  73.1 ± 14 **    
BMI (Kg/m2) Baseline 24.4 ± 0.3 23.6 ± 0.3   25.1 ± 0.4 §§ 0.1 0.009 0.08 
  Follow-up 24.2 ± 0.3 23.6 ± 0.3   24.8 ± 0.4 §       
Body Fat (%) Baseline 25 ± 8 23 ± 8  27 ± 8  0.006 0.021 0.06 
 Follow-up 24 ± 9 23 ± 9  26 ± 9     
Blood Pressure                 
Heart Rate (bpm) Baseline 70 ± 13 71 ± 13  69 ± 13  0.3 0.9 0.4 
 Follow-up 68 ± 12 68 ± 12  68 ± 13     
Brachial SBP (mmHg) Baseline 121 ± 14 119 ± 11   124 ± 15 §§ <.001 0.026 0.049 
  Follow-up 117 ± 13 116 ± 10 * 118 ± 15 ***       
Brachial DBP (mmHg) Baseline 75 ± 7 73 ± 5  76 ± 8 §§ <.001 0.020 0.028 
 Follow-up 72 ± 7 72 ± 5  73 ± 8 ***    
Central SBP (mmHg) Baseline 112 ± 13 109 ± 11   115 ± 14 §§ <.001 0.004 0.043 
  Follow-up 108 ± 13 106 ± 10   109 ± 15 ***       
Central DBP (mmHg) Baseline 76 ± 7 75 ± 5  78 ± 8 §§ <.001 0.030 0.011 
 Follow-up 74 ± 7 73 ± 5 * 74 ± 8 ***    
Central MAP (mmHg) Baseline 87 ± 8 86 ± 7   91 ± 10 §§ <.001 0.009 0.016 
  Follow-up 85 ± 10 84 ± 7 * 86 ± 10 ***       
                
Pulse Wave Analysis                
PWV Arch (m/s) Baseline 4.7 ± 1.4 3.9 ± 0.6  5.6 ± 1.6 §§§ 0.2 <.001 0.4 
 Follow-up 4.6 ± 1.2 3.9 ± 0.6  5.3 ± 1.3     
Formatted: Superscript
Table 2
PWV Descending aorta (m/s) Baseline 8.3 ± 2.5 8.2 ± 2.6   8.5 ± 2.3   0.1 0.060 0.9 
  Follow-up 7.9 ± 2.4 7.6 ± 4.9   8.2 ± 2.5         
PWV Whole aorta (m/s) Baseline 6.0 ± 1.5 5.3 ± 1  6.7 ± 1.7 §§§ 0.038 <.001 0.8 
 Follow-up 5.7 ± 1.4 5.1 ± 0.7  6.5 ± 1.7     
SAC (ml/m²) Baseline 3.0 ± 0.8 3.2 ± 0.7   2.9 ± 0.9 §§ 0.022 0.001 >0.9 
  Follow-up 3.2 ± 0.7 3.4 ± 0.7   3 ± 0.7 §§       
SVR (dyn·s/cm5) Baseline 1135 ± 262 1052 ± 239  1225 ± 275  0.034 0.001 0.5 
 Follow-up 1092 ± 246 1029 ± 255  1160 ± 239     
CMR                
LV EDV i (ml/m2) Baseline 86 ± 14 90 ± 14   82 ± 13 §§ 0.014 <.001 0.027 
  Follow-up 88 ± 14 93 ± 15 ** 82 ± 13 §§§       
LV ESV i (ml/m2) Baseline 30 ± 7 33 ± 8  28 ± 6 §§ 0.019 <.001 0.023 
 Follow-up 31 ± 8 35 ± 8 ** 28 ± 7 §§§    
SV i (ml/m2) Baseline 56 ± 10 58 ± 10   54 ± 9 § 0.4 0.008 0.5 
  Follow-up 57 ± 9 59 ± 10   54 ± 8         
LV EF (%) Baseline 0.65 ± 0.05 0.64 ± 0.05  0.66 ± 0.05 § 0.4 0.001 0.254 
 Follow-up 0.64 ± 0.05 0.63 ± 0.05  0.66 ± 0.05     
CO (l/min) Baseline 6.7 ± 1.6 7.1 ± 1.7   6.3 ± 1.5 § 0.2 0.003 0.8 
  Follow-up 6.6 ± 1.7 7 ± 1.8   6.1 ± 1.5         
LV mass i (g/m2) Baseline 62 ± 12 65 ± 12  59 ± 12  <.001 <.001 0.8 
 Follow-up 65 ± 13 68 ± 12 *** 62 ± 13 ***    
LV mass/volume ratio Baseline 0.72 ± 0.1 0.71 ± 0.1   0.73 ± 0.1   0.001 0.049 0.06 
  Follow-up 0.74 ± 0.1 0.73 ± 0.1   0.76 ± 0.1 **       
RV EDV i (ml/m2) Baseline 88 ± 15 92 ± 15  82 ± 13  0.001 <.001 0.6 
 Follow-up 90 ± 16 96 ± 17 ** 85 ± 14     
RV ESV i (ml/m2) Baseline 35 ± 10 39 ± 9   29 ± 8   0.001 <.001 0.7 
  Follow-up 36 ± 11 41 ± 10 ** 31 ± 9         
RV SV i (ml/m2) Baseline 53 ± 9 53 ± 10  53 ± 9  0.08 0.9 0.6 
 Follow-up 54 ± 9 55 ± 9  54 ± 8     
RV EF (%) Baseline 0.61 ± 0.06 0.58 ± 0.05   0.65 ± 0.07 §§§ 0.4 <.001 0.7 
Formatted: Not Superscript/ Subscript
  Follow-up 0.61 ± 0.05 0.57 ± 0.05   0.64 ± 0.07         
LA volume i (ml/m2) Baseline 51 ± 29 51 ± 28  50 ± 31  0.9 0.8 0.09 
 Follow-up 50 29  48 ± 26  52 ± 31     
Native myocardial T1 (msec) Baseline 1009 ± 29 1009 ± 28   1009 ± 28   0.3 0.4 0.8 
  Follow-up 1006 ± 33 1006 ± 33   1006 ± 33         
Synthetic ECV (%) Baseline 26.3 ± 3 25.8 ± 3  26.7 ± 3  0.8 0.1 0.2 
 Follow-up 26.3 ± 3 26 ± 3  26.6 ± 3     
CPET                
Exercise time (secs) Baseline 674 ± 133 594 ± 104   760 ± 104   0.01 <.001 0.037 
  Follow-up 695 ± 127 630 ± 115 ** 764 ± 100         
Peak VO2 (ml/kg/min) Baseline 34.5 ± 7.5 37.1 ± 6.8  31.4 ± 7  0.035 <.001 0.3 
 Follow-up 35.6 ± 8.3 38.5 ± 8 * 31.9 ± 7     
Peak power (W) Baseline 216 ± 57 222 ± 54   209 ± 59   0.002 0.012 0.001 
  Follow-up 220 ± 60 232 ± 59 ** 208 ± 60         
% of VO2 max Baseline 109 ± 17 106 ± 16  113 ± 18  0.2 0.1 0.4 
 Follow-up 113 ± 19 110 ± 17  116 ± 21     
Peak HR (bpm) Baseline 163 ± 15 168 ± 14  159 ± 16  0.8 <.001 0.07 
 Follow-up 165 ± 15 173 ± 15  158 ± 14     
RQ Baseline 1.22 ± 0.09 1.20 ± 0.09  1.24 ± 0.08 * 0.02 0.01 0.51 
 Follow-up 1.21 ± 0.08 1.19 ± 0.10  1.21 ± 0.07     
 
Table 2: Baseline and post-marathon tests results for the patients who completed the study, whole sample, U35 and O35. Data are expressed 
as mean ±SD.  
* = p pre vs post <0.05; ** = p pre vs post <0.01; *** = p pre vs post <.001; § = p U35 vs O35 <0.05; §§ = p U35 vs O35 <0.01; §§§ = p U35 vs 
O35 <.001. 
BMI: body mass index. SBP: systolic blood pressure. DBP: diastolic blood pressure. MAP: mean arterial pressure. PWV: pulse wave velocity. SAC: 
systemic arterial compliance. SVR: systemic vascular resistances. LV: left ventricle. EDV: end diastolic volume. ESV: end systolic volume. SV: 
stroke volume. EF: ejection fraction. CO: cardiac output. RV: right ventricle. LA: left atrium. ECV: extra cellular volume.  
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